10X Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . 10X Genomics
TXG Stock  USD 10.76  0.42  4.06%   
10X Genomics financial statements provide useful quarterly and yearly information to potential 10X Genomics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on 10X Genomics financial statements helps investors assess 10X Genomics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting 10X Genomics' valuation are summarized below:
Gross Profit
414.8 M
Profit Margin
(0.30)
Market Capitalization
1.3 B
Enterprise Value Revenue
1.5616
Revenue
610.8 M
There are over one hundred nineteen available fundamental signals for 10X Genomics, which can be analyzed over time and compared to other ratios. Active traders should verify all of 10X Genomics prevailing fundamental drivers against the trend between 2010 and 2025 to make sure the company can sustain itself this quarter and beyond. The current Market Cap is estimated to decrease to about 5.2 B. Enterprise Value is estimated to decrease to about 5 B

10X Genomics Total Revenue

412.3 Million

Check 10X Genomics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among 10X Genomics' main balance sheet or income statement drivers, such as Tax Provision of 3.9 M, Net Interest Income of 19.4 M or Interest Income of 19.4 M, as well as many indicators such as Price To Sales Ratio of 2.69, Dividend Yield of 0.0 or PTB Ratio of 2.31. 10X financial statements analysis is a perfect complement when working with 10X Genomics Valuation or Volatility modules.
  
Check out the analysis of 10X Genomics Correlation against competitors.
For more detail on how to invest in 10X Stock please use our How to Invest in 10X Genomics guide.

10X Genomics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets779.2 M918.6 M436 M
Slightly volatile
Short and Long Term Debt Total67.1 M82.6 M39.3 M
Slightly volatile
Other Current Liabilities62.7 M69.8 M37.1 M
Slightly volatile
Total Current Liabilities99.2 M117.6 M61 M
Slightly volatile
Other Liabilities5.3 M5.5 M13 M
Pretty Stable
Property Plant And Equipment Net196.8 M309.9 M104.8 M
Slightly volatile
Current Deferred Revenue21.7 M20.7 M5.9 M
Slightly volatile
Accounts Payable13.7 M12.9 M9.5 M
Slightly volatile
Cash372.8 M344.1 M213.7 M
Slightly volatile
Non Current Assets Total230.2 M334.2 M122.3 M
Slightly volatile
Non Currrent Assets Other3.9 M4.1 M8.1 M
Pretty Stable
Other Assets8 M8.5 M11.9 M
Slightly volatile
Long Term Debt18.9 M22.8 M13.6 M
Slightly volatile
Cash And Short Term Investments412.5 M393.4 M234.2 M
Slightly volatile
Net Receivables71.5 M87.9 M42.8 M
Slightly volatile
Common Stock Total Equity1.8 K2.3 K1.4 K
Slightly volatile
Common Stock Shares Outstanding91.6 M120.5 M52.4 M
Slightly volatile
Long Term Debt Total18.9 M22.8 M13.6 M
Slightly volatile
Liabilities And Stockholders Equity779.2 M918.6 M436 M
Slightly volatile
Non Current Liabilities Total104.4 M90.9 M144.4 M
Slightly volatile
Capital Surpluse2.2 B2.1 B748.9 M
Slightly volatile
Inventory49.1 M83.1 M27.5 M
Slightly volatile
Other Current Assets19.6 M20 M11 M
Slightly volatile
Other Stockholder Equity1.3 B2.2 B668.3 M
Slightly volatile
Total Liabilities176.6 M208.5 M203.7 M
Pretty Stable
Property Plant And Equipment Gross221.5 M432.9 M117.5 M
Slightly volatile
Short and Long Term Debt6.7 M11.4 M6.6 M
Slightly volatile
Total Current Assets549 M584.4 M313.6 M
Slightly volatile
Non Current Liabilities Other4.8 M5 M11.8 M
Slightly volatile
Net Working Capital449.7 M466.8 M252.6 M
Slightly volatile
Short Term Debt10.9 M9.3 M7.5 M
Slightly volatile
Common Stock1.9 K2.3 K1.5 K
Slightly volatile
Property Plant Equipment349.4 M332.7 M105 M
Slightly volatile
Capital Stock2 K2.3 K1.5 K
Slightly volatile

10X Genomics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Tax Provision3.9 M4.9 M2 M
Slightly volatile
Interest Income19.4 M18.4 M4.3 M
Slightly volatile
Depreciation And Amortization24.5 M43.7 M14.6 M
Slightly volatile
Interest Expense3.8 K4 K940 K
Pretty Stable
Selling General Administrative233.2 M344.3 M141 M
Slightly volatile
Total Revenue412.3 M610.8 M244.3 M
Slightly volatile
Gross Profit307.9 M414.5 M185.7 M
Slightly volatile
Other Operating Expenses526.7 M805.3 M311.4 M
Slightly volatile
Research Development178.6 M264.7 M106.4 M
Slightly volatile
Cost Of Revenue104.4 M196.3 M58.6 M
Slightly volatile
Total Operating Expenses422.3 M609 M252.9 M
Slightly volatile
Reconciled Depreciation25.1 M43.7 M14.9 M
Slightly volatile
Income Tax Expense3.9 M4.9 M2 M
Slightly volatile
Selling And Marketing Expenses3.3 M3.8 M2.2 M
Slightly volatile

10X Genomics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation83.4 M140.7 M43.9 M
Slightly volatile
Begin Period Cash Flow344.8 M359.3 M196.5 M
Slightly volatile
Other Cashflows From Financing Activities10.4 M10.9 M24.8 M
Very volatile
Depreciation25.1 M43.7 M14.9 M
Slightly volatile
Other Non Cash Items3.4 M3.6 M20.6 M
Pretty Stable
Capital Expenditures11.8 M12.4 M26.5 M
Slightly volatile
Total Cash From Financing Activities10.4 M10.9 M77.5 M
Pretty Stable
End Period Cash Flow386.4 M344.1 M220.7 M
Slightly volatile
Change To Netincome111.7 M158.6 M64.3 M
Slightly volatile
Change To Liabilities11.1 M8.5 M7.4 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio2.692.831911.9579
Pretty Stable
Days Sales Outstanding69.8552.505666.0851
Slightly volatile
Stock Based Compensation To Revenue0.120.23040.0939
Slightly volatile
Capex To Depreciation0.270.28351.627
Pretty Stable
EV To Sales2.282.403811.296
Pretty Stable
Inventory Turnover2.662.36212.333
Very volatile
Days Of Inventory On Hand138155168
Very volatile
Payables Turnover15.9715.20675.638
Slightly volatile
Sales General And Administrative To Revenue0.640.630.621
Slightly volatile
Research And Ddevelopement To Revenue0.340.43340.4282
Slightly volatile
Capex To Revenue0.01930.02030.0845
Slightly volatile
Cash Per Share5.793.26614.7995
Pretty Stable
Days Payables Outstanding22.824.0026122
Slightly volatile
Intangibles To Total Assets0.02950.0220.0327
Slightly volatile
Net Debt To EBITDA1.851.95134.306
Pretty Stable
Current Ratio4.184.96794.2207
Slightly volatile
Receivables Turnover4.686.95165.548
Pretty Stable
Capex Per Share0.09770.10290.4541
Pretty Stable
Revenue Per Share6.285.07085.9289
Pretty Stable
Interest Debt Per Share1.090.68590.9941
Pretty Stable
Debt To Assets0.120.08990.1222
Slightly volatile
Operating Cycle189207233
Very volatile
Days Of Payables Outstanding22.824.0026122
Slightly volatile
Ebt Per Ebit0.870.91331.3465
Pretty Stable
Quick Ratio3.844.26143.8894
Slightly volatile
Net Income Per E B T0.821.02771.0009
Pretty Stable
Cash Ratio4.032.92493.0268
Slightly volatile
Cash Conversion Cycle128183109
Slightly volatile
Days Of Inventory Outstanding138155168
Very volatile
Days Of Sales Outstanding69.8552.505666.0851
Slightly volatile
Fixed Asset Turnover1.871.97077.0
Slightly volatile
Debt Ratio0.120.08990.1222
Slightly volatile
Price Sales Ratio2.692.831911.9579
Pretty Stable
Asset Turnover0.70.66490.7759
Slightly volatile
Gross Profit Margin0.850.67860.8111
Slightly volatile

10X Genomics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap5.2 B5.9 B3.8 B
Slightly volatile
Enterprise Value5 B5.7 B3.7 B
Slightly volatile

10X Fundamental Market Drivers

Forward Price Earnings196.0784
Cash And Short Term Investments393.4 M

10X Upcoming Events

15th of February 2024
Upcoming Quarterly Report
View
1st of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
15th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About 10X Genomics Financial Statements

10X Genomics stakeholders use historical fundamental indicators, such as 10X Genomics' revenue or net income, to determine how well the company is positioned to perform in the future. Although 10X Genomics investors may analyze each financial statement separately, they are all interrelated. For example, changes in 10X Genomics' assets and liabilities are reflected in the revenues and expenses on 10X Genomics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in 10X Genomics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue20.7 M21.7 M
Total Revenue610.8 M412.3 M
Cost Of Revenue196.3 M104.4 M
Stock Based Compensation To Revenue 0.23  0.12 
Sales General And Administrative To Revenue 0.63  0.64 
Research And Ddevelopement To Revenue 0.43  0.34 
Capex To Revenue 0.02  0.02 
Revenue Per Share 5.07  6.28 
Ebit Per Revenue(0.32)(0.33)

Currently Active Assets on Macroaxis

VVisa Class A
CRMSalesforce
CRMSalesforce
MSFTMicrosoft
VVisa Class A
When determining whether 10X Genomics is a strong investment it is important to analyze 10X Genomics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact 10X Genomics' future performance. For an informed investment choice regarding 10X Stock, refer to the following important reports:
How To Invest In 10X
Details
Is 10X Stock a good investment?
Details
What is 10X Genomics' Net Worth?
Details
Largest Life Sciences Tools & Services Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of 10X Genomics Correlation against competitors.
For more detail on how to invest in 10X Stock please use our How to Invest in 10X Genomics guide.
You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of 10X Genomics. If investors know 10X will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about 10X Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.52)
Revenue Per Share
5.071
Quarterly Revenue Growth
(0.10)
Return On Assets
(0.13)
Return On Equity
(0.25)
The market value of 10X Genomics is measured differently than its book value, which is the value of 10X that is recorded on the company's balance sheet. Investors also form their own opinion of 10X Genomics' value that differs from its market value or its book value, called intrinsic value, which is 10X Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because 10X Genomics' market value can be influenced by many factors that don't directly affect 10X Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between 10X Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if 10X Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, 10X Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY